Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | NAMPT | P43490 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646864 | 1.00 | HTR2C (0.53) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15645922 | 1.00 | HTR2C (0.53) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4538691 | 0.97 | HTR2C (0.56) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4538687 | 0.97 | HTR2C (0.56) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5019738 | 0.97 | HTR2C (0.56) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15646514 | 0.84 | NAMPT (0.48) | NAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15647266 | 0.83 | NAMPT (0.58) | HTR2CNAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15647661 | 0.83 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15645210 | 0.83 | GID4 (0.48) | HTR2CHTR2BHTR6KDM4E | |
| SCHEMBL15646384 | 0.83 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | HTR2C 2072/4885NAMPT 4652/4885CYP3A4 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.